I believe in cutting to the chase. If the drug's s
Post# of 5789
If the efficacy isn't there, the market punishes that.
So, we're left with most of the drugs that either had the bad data, but better performance in the wider 'approved' patient base, or most of the drugs whose studies were more rigorous. And such rigor is born out in a safe and efficacious drug.
You're left with explaining which drugs you don't 'like' and explaining why you want them pulled from the market.
That has to be the end game in all this. What else are you arguing on behalf of?